
Disc Medicine to webcast APOLLO Phase 3 trial results of bitopertin for erythropoietic protoporphyria
Disc Medicine announced a webcast on October 19, 2026, to discuss topline results from its APOLLO Phase 3 trial of bitopertin, an investigational oral drug for erythropoietic protoporphyria (EPP). Bitopertin targets glycine transporter 1 to modulate ...





